Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.

Abstract: A method and apparatus for processing data packets in flow-aware network nodes is disclosed for storing flow data without altering transmission data throughput for a limited cost. The method and apparatus for processing data packets in flow-aware network nodes includes alternate usage of a fast access internal memory and a slower speed access external memory which provides low latency yet comprehensive flow-awareness. The method for processing data packets in flow-aware network nodes is particularly useful for overcoming requiring extensive usage of fast access memory of flow-aware network nodes known in the art.

Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.

Abstract: The present invention refers to a method for reducing energy consumption in a packet processing linecard of a packet transmission network, said packet processing linecard comprising a plurality of microprocessors aimed at processing packet traffic wherein the number of active microprocessors is dynamically adjusted as a function of the computation of a traffic estimator based on a recurrent estimation of at least two statistical parameters including the average and a parameter representative of the statistical distribution of the packet traffic.

Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.

Abstract: In one embodiment, a network communication node receives data and includes a plurality of processors aimed at processing data at a given layer of communication so as to route them towards a given destination. The node determines at least one layer of communication for processing the received data.

Abstract: The invention concerns a method for scheduling packets belonging to a plurality of flows received at a router. It is also provided the system for carrying out the method. According to the invention, a single packet queue is used for storing said packets, said single packet queue being adapted to be divided into a variable number of successive sections which are created and updated dynamically as a function of each received packet, each section being of variable size and a section load threshold for each flow of said plurality of flows being allocated to each section. The method further comprises insertion (S11; S22; S210; S222; S230) of each received packet of a given flow in one of said successive sections as a function of said given flow and of the corresponding section load threshold.

Abstract: Biomarkers can be assessed for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, or the stage or progression of a disease. Circulating biomarkers from a bodily fluid can be used in profiling of physiological states or determining phenotypes. These include nucleic acids, protein, and circulating structures such as vesicles. Biomarkers can be used for theranostic purposes to select candidate treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. The biomarkers can be circulating biomarkers, including vesicles and microRNA.

Abstract: The present invention refers to a method for reducing energy consumption in a packet processing linecard of a packet transmission network, said packet processing linecard comprising a plurality of microprocessors aimed at processing packet traffic wherein the number of active microprocessors is dynamically adjusted as a function of the computation of a traffic estimator based on a recurrent estimation of at least two statistical parameters including the average and a parameter representative of the statistical distribution of the packet traffic.

Abstract: A method and apparatus for processing data packets in flow-aware network nodes is disclosed for storing flow data without altering transmission data throughput for a limited cost. The method and apparatus for processing data packets in flow-aware network nodes includes alternate usage of a fast access internal memory and a slower speed access external memory which provides low latency yet comprehensive flow-awareness. The method for processing data packets in flow-aware network nodes is particularly useful for overcoming requiring extensive usage of fast access memory of flow-aware network nodes known in the art.

Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.

Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.

Abstract: Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.

Abstract: The present invention relates to a method of operating a scheduler (100) of a crossbar switch (200), wherein said scheduler (100) comprises a tree structure comprising an input stage (IS) with a plurality of entry modules (E—1, E—2, . . . ) and at least one decider stage (DS—1, DS—2, . . . ), wherein each decider stage (DS—1, DS—2, . . . ) comprises at least one decider module (D—1—1, D—2—1, . . . ), wherein one or more modules (E—1, E—2, D—1—1, D—1—2, . . . ) are connected to a decider module (D—1—1, D—2—1, . . . ) of a subsequent decider stage (DS—1, DS—2, . . . ), wherein a packet reference is forwarded from said input stage (IS) or a decider stage to a subsequent decider stage depending on a forwarding decision that is made in a decider module (D—1—1, D—2—1, . . .

Abstract: A device for coupling high-frequency signals between a first component and a second component is adapted to supply a first bias voltage-current pair to the first component and a second bias voltage-current pair to the second component.

Abstract: Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin.